Our global team has deep scientific knowledge, extensive pharmaceutical experience as well as proven clinical and business acumen.
Laura Benjamin, PhD
Founder and CEO
BA in Biology from Barnard College, Columbia University
PhD in Molecular Biology from the University of Pennsylvania
Laura brings scientific vision and leadership experience from her years as faculty at Harvard Medical School and Vice President at ImClone Systems and Eli Lilly. She has focused her scientific career on cancer biology and clinical biomarker strategies.
David Malek, MBA
Chief Business Officer
MBA from Tuck School of Management, Dartmouth University
David brings experience in business development as well as executive managerial experience in public companies, Sanofi and BiolineRx.
Hagop Youssoufian, MD
Acting Chief Medical Officer
MD from University of Massachusetts Medical School
Fellowships in Genetics at Johns Hopkins and Hematology-Oncology at Massachusetts General Hospital
Hagop is an experienced oncology drug developer with tenures in several pharmaceutical and biotech companies, including as Chief Medical Officer at ImClone-Lilly and as President of R&D at Ziopharm. He was involved in the development and approval of multiple oncology biologic products, such as Erbitux®, Cyramza® and Taxotere®.